News Center

Company news

Media reports

29

2022-08

Kintor Pharma Announces 2022 Interim Results and Recent Business Highlights

Suzhou, August 29, 2022 - 真人直营投注网站 (“Kintor Pharma” or “the Company”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced its 2022 interim results and released an update on its recent business highlights.

Picture Name

09

2022-08

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

Suzhou, August 9, 2022 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92 subjects for its phase I clinical trial of GT20029 in China for the treatment of androgenetic alopecia (AGA) and acne on August 8, 2022.

Picture Name

03

2022-08

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

Suzhou, August 3, 2022 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company completed the enrollment of 121 patients for its phase II clinical trial of KX-826 ("pyrilutamide") in the United States for the treatment of male androgenetic alopecia (AGA) patients on August 1, 2022.

Picture Name

18

2022-07

Kintor Scientists Published Results of Study Showing Pruxelutamide's Inhibitory Effects on Acute Lung Injury and Its Molecular Mechanism of Anti-Inflammatory Response

Recently, Kintor Pharma scientists published results of a study titled " Inhibitory Effects of GT0918 on Acute Lung Injury and the Molecular Mechanisms of Anti-inflammatory Response " in the preprint journal bioRxiv. The study demonstrated that pruxelutamide (GT0918) is an effective therapeutic drug for severe COVID-19 patients, in addition to mild to moderate COVID-19 patients treatment.

Picture Name

08

2022-07

Kintor Pharma: Q2 2022 Business Update at a Glance

Kintor Pharma Q2 2022 Business Update at a Glance

Picture Name

14

2022-06

Kintor Pharma and Etana's Collaboration on Pruxelutamide's COVID-19 Project Awarded with Belt and Road Innovation Project and Fund Support from the Science and Technology Department of Jiangsu Province

Suzhou, June 14, 2022 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that its “clinical trial cooperative research and development and overseas application demonstration of the anti-COVID-19 drug (pruxelutamide, used to be called proxalutamide)” project was selected as one of the Belt and Road Innovation Cooperation Projects and was included in the list of proposed projects for special fund supported by the Jiangsu Provincial Department of Science and Technology (Innovation Support Plan for International Science and Technology Cooperation/Hong Kong, Macao, and Taiwan Science and Technology Cooperation). Kintor Pharma and Etana, an Indonesian company, developed the project together.

Picture Name
< 1...567...22 > proceed page

Kintor